Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation

Ji Won Kim, Byung Su Kim, Soo Mee Bang, Inho Kim, Dong Hwan Kim, Won Seog Kim, Deok Hwan Yang, Je Jung Lee, Je Hwan Lee, Jin Seok Kim, Sang Kyun Sohn, Ho Young Yhim, Jae Yong Kwak, Sung Soo Yoon, Jong Seok Lee, Seonyang Park, Byoung Kook Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

There are few treatment options for patients with non-Hodgkin lymphoma (NHL) who experienced progression after high-dose chemotherapy (HDC) with autologous stem cell transplantation (auto-SCT). The role of allogeneic stem cell transplantation (allo-SCT) in these patients has not been clarified yet. In this study, we report clinical outcomes of allo-SCT in patients with NHL who experienced progression after HDC with auto-SCT. Patients were enrolled from seven hospitals in Korea. A total of 38 patients were included: 18 patients (47.4%) underwent myeloablative conditioning and 20 patients (52.6%) reduced intensity conditioning. Overall response rate was 73.3%. Median event-free survival was 6.3 months. Median overall survival (OS) was 19.0 months. Estimated 5-year survival rate was 35.0%. Acute graft-versus-host disease developed in 13 patients (34.2%). Transplant-related mortality (TRM) was 21.1% (eight patients). Ann Arbor stage (p = 0.022), performance status (p < 0.001), and baseline serum albumin level (p = 0.010) were significant risk factors for OS. Performance status (p = 0.022) was a significant risk factor for TRM. Eight patients with persistent or progressive disease received donor lymphocyte infusion, and two of them achieved complete remission. In conclusion, despite high TRM, allo-SCT is a viable option for patients with NHL who underwent progression after HDC with auto-SCT.

Original languageEnglish
Pages (from-to)1409-1418
Number of pages10
JournalAnnals of Hematology
Volume90
Issue number12
DOIs
Publication statusPublished - 2011 Dec 1

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Kim, J. W., Kim, B. S., Bang, S. M., Kim, I., Kim, D. H., Kim, W. S., Yang, D. H., Lee, J. J., Lee, J. H., Kim, J. S., Sohn, S. K., Yhim, H. Y., Kwak, J. Y., Yoon, S. S., Lee, J. S., Park, S., & Kim, B. K. (2011). Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. Annals of Hematology, 90(12), 1409-1418. https://doi.org/10.1007/s00277-011-1227-y